Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Oxford Bio Abandons Prostate Cancer Vaccine Study

FDAnews Drug Daily Bulletin

Oct. 11, 2012 | Vol. 9 No. 200

Oxford Bio Abandons Prostate Cancer Vaccine Study

Britain’s Oxford BioMedica said it was closing a mid-stage clinical trial of its cancer vaccine TroVax in U.S. patients with prostate cancer, dealing a further blow to the troubled product.
Reuters

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Mylan Launches Generic Tricor Tablets Is the FDA Approving too Many Drugs Starting with X and Z?Court Rejects Merck Deal Over Vioxx Citizens in Poor EU States Can’t Afford Medicines, Health Promoters Say

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.